VFA
FENC icon

Valeo Financial Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Valeo Financial Advisors’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-20
Closed – – 1575
2018
Q4 		$0 Hold
20
– – ﹤0.01% 1569
2018
Q3 		$0 Buy
+20
New +$186 ﹤0.01% 1806

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Valeo Financial Advisors's FENC Position: Q1 2019 in Review

Valeo Financial Advisors sold out of Fennec Pharmaceuticals (FENC) in Q1 2019, closing a stake of 20 shares.

Valeo Financial Advisors first reported a position in FENC in Q3 2018 and held it in 2 quarters. The position peaked at $0 in Q4 2018. 49 funds tracked by Wall St. Rank hold FENC as of Q1 2019.

  • Valeo Financial Advisors reported no remaining Fennec Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Valeo Financial Advisors sold 20 Fennec Pharmaceuticals shares in Q1 2019.
  • Valeo Financial Advisors first reported a position in Fennec Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Valeo Financial Advisors's Fennec Pharmaceuticals position peaked at $0 in Q4 2018.
  • 49 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2019.

Based on Valeo Financial Advisors's 13F filing for Q1 2019, filed 12 Apr 2019.